B7/CD28 interaction inhibitor 1 |
Catalog No.GC60618 |
El inhibidor 1 de la interacciÓn B7/CD28 (compuesto 6b) es un potente inhibidor de la interacciÓn B7.1-CD28 con una IC50 de 50 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 635324-72-0
Sample solution is provided at 25 µL, 10mM.
B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC50 of 50 nM[1].
Bivalent CTLA4 homodimers bridge bivalent B7.1 homodimers to form an unusually stable signaling complex. Blocking B7/CD28 interactions with monoclonal antibodies or soluble receptors results in immunosuppression and enhanced allograft survival, while B7/CTLA-4 blockade results in enhanced antitumor immune responses. The interaction of co-stimulatory molecules on T cells with B7 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases[1].
[1]. Green NJ, et al. Structure-activity studies of a series of dipyrazolo[3,4-b:3',4'-d]pyridin-3-ones binding to the immune regulatory protein B7.1. Bioorg Med Chem. 2003 Jul 3;11(13):2991-3013.
Average Rating: 5
(Based on Reviews and 36 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *